Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Melanoma: Update Bulletin #3 [August 2018]

Product Code:
596200974
Publication Date:
August 2018
Format:
PDF
Price:
$1,095

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from North America and Europe on a variety of recent events in the melanoma market. KOLs gave their candid insights on the following events: Array BioPharma’s BRAF inhibitor encorafenib (Braftovi) was approved in the US, in combination with binimetinib (Mektovi), a MEK inhibitor as a treatment for BRAFV600E or BRAFV600K mutation-positive unresectable or metastatic melanoma; Iovance Biotherapeutics announcing that the first patient was dosed in the ongoing Phase II (C-144-01) trial of LN-144 (lifileucel); and Idera Pharmaceuticals announcing results from the ongoing Phase I/II ILLUMINATE-204 study.

Business Questions:

• How do KOLs view the arrival of Array’s Braftovi/Mektovi in the BRAF/MEK market?
• Will the Braftovi/Mektovi combination be able to compete effectively?
• How will the BRAF/MEK market evolve with newer combination trials with immunotherapies?
• What do experts think of Iovance’s cell based TIL therapy lifileucel?
• What do KOLs suggest ACTs should be studied in combination with?
• Can ACTs approach provide a breakthrough to replace current MM treatment options?
• Are KOLs excited by the potential of tilsotolimod/Yervoy combination?
• What do KOLs think about the rationale for the tilsotolimod/Yervoy study?
• Can tilsotolimod/Yervoy be effective in patients’ refractory to anti-PD-1 therapy?
• Do KOLs think the tilsotolimod/Yervoy combination can reach durable milestones?





customer.service@firstwordpharma.com

All Contents Copyright © 2018 Doctor's Guide Publishing Limited All Rights Reserved